Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea.

ABSTRACT:

Importance

First-line systemic therapy for morphea includes methotrexate with or without systemic corticosteroids. When this regimen is ineffective, not tolerated, or contraindicated, a trial of mycophenolate mofetil (MMF) or mycophenolic acid (MPA)-referred to herein as mycophenolate-is recommended; however, evidence to support this recommendation remains weak.

Objective

To evaluate the effectiveness and tolerability of mycophenolate for the treatment of morphea.

Design, setting, and participants

A retrospective cohort study was conducted from January 1, 1999, to December 31, 2018, among 77 patients with morphea from 8 institutions who were treated with mycophenolate.

Main outcomes and measures

The primary outcome was morphea disease activity, severity, and re

SUBMITTER: Arthur M 

PROVIDER: S-EPMC7113833 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature